Company profile: LumiraDx
1.1 - Company Overview
Company description
- Provider of a point-of-care diagnostic platform delivering lab-comparable performance via a portable instrument, microfluidic test strips, and digital connectivity, plus cloud-based reporting, analytics, and decision support. Offers COVID-19 antigen and antibody tests and microfluidic immunoassays including NT-proBNP, D-Dimer, and INR.
Products and services
- 'LumiraDx Platform: A lab-comparable point-of-care diagnostic system featuring a portable instrument, microfluidic test strip, and digital connectivity, supporting a menu of tests with lab-comparable results'
- 'Cloud-based technology: A cloud-based service delivering data reporting, analytics, and decision support for healthcare professionals to practically and reliably support health care transformation goals'
- 'COVID-19 Antigen and Antibody tests: Development-stage assays for detecting COVID-19 infection and immune response, with over 30 tests in development across various assay technologies'
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to LumiraDx
Navigenics
HQ: United States
Website
- Description: Provider of personal genomics services using genetic testing to assess individual risk for health conditions, educating and empowering individuals and their physicians with knowledge of genetic predispositions to motivate prevention, enable earlier diagnosis, and support appropriate disease management to lessen disease impact.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Navigenics company profile →
Numares
HQ: Germany
Website
- Description: Provider of software-based diagnostic test systems and commercial NMR analytics in Europe, offering the full scope of up-to-date NMR analytics from one source, with expert assistance for optimal results; fast, cost-efficient, and reliable.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Numares company profile →
Cordant Health Solutions
HQ: United States
Website
- Description: Provider of drug testing and case-management solutions for health, chronic pain, and criminal justice, including Cordant Sentry for automated patient testing randomization, real-time results, and compliance alerts; urine, oral fluid, hair, and blood drug testing; and behavioral health solutions with laboratory testing, pharmacy services, and adherence monitoring.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cordant Health Solutions company profile →
Roche
HQ: Switzerland
Website
- Description: Provider of pharmaceuticals and in-vitro diagnostics, including diagnostic tests and instruments for cancer, diabetes, and infectious diseases; develops medicines for oncology, neurology, virology, inflammation, metabolism, CNS, ophthalmology, immunology, and transplantation; offers digital health solutions for virtual care, decision support, and self-monitoring, plus diabetes management devices and services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Roche company profile →
Anbio
HQ: Germany
Website
- Description: Provider of in vitro diagnostic medical devices and solutions, developing and manufacturing laboratory, at-home, and point-of-care tests for cancer, cardiovascular diseases, infectious diseases, and pharmacogenomics; conducts research and provides diagnosis globally.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anbio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for LumiraDx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to LumiraDx
2.2 - Growth funds investing in similar companies to LumiraDx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for LumiraDx
4.2 - Public trading comparable groups for LumiraDx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →